22-09-2025, 22:02

Angelini Pharma Signs Exclusive Option Agreement With Sovargen To License Global Development and Commercialization Rights For Innovative Brain Health Asset

Notified -
Globe Newswire22-09-2025, 22:02
21-10-2024, 11:00

Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset
Globe Newswire21-10-2024, 11:00
11-06-2024, 01:33

London Research & Pharmaceuticals (LRP) Presents the Advancement of LRP-661, Their Lead Drug Candidate, at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) Conference in Madrid, Spain, 5-8 May 2024
Globe Newswire11-06-2024, 01:33
11-06-2024, 01:33

London Research & Pharmaceuticals (LRP) Presents the Advancement of LRP-661, Their Lead Drug Candidate, at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) Conference in Madrid, Spain, 5-8 May 2024

Notified -
Globe Newswire11-06-2024, 01:33